基于 DNA 超分子水凝胶的保护性 NK 细胞储库用于增强三阴性乳腺癌治疗
Protective NK Cell Reservoir Based on DNA Supramolecular Hydrogel for Enhanced Triple-Negative Breast Cancer Therapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
辅助免疫细胞治疗联合全身治疗对实体瘤的疗效
英文原题：Efficacy of Adjuvant Immune-cell Therapy Combined With Systemic Therapy for Solid Tumors.
查看英文原题
Efficacy of Adjuvant Immune-cell Therapy Combined With Systemic Therapy for Solid Tumors.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
辅助免疫细胞治疗联合其他全身性治疗可能为实体瘤患者提供生存获益。
研究思路结论见上方概要
背景
手术切除后辅助全身治疗的疗效仍不令人满意；因此，需要新的治疗策略。我们旨在探讨使用活化T淋巴细胞的辅助免疫细胞治疗联合或不联合树突状细胞疫苗，与标准辅助全身治疗联合，对实体瘤患者生存的疗效，这些实体瘤包括肺癌、胃癌、胰腺癌、结直肠癌和乳腺癌。
方法
本研究共纳入141例实体瘤患者。通过单因素和多因素分析，探讨了总生存期和无病生存期与年龄、性别、体能状态评分、临床分期、治疗策略及生存状态等多种临床因素的相关性。
结果
多因素分析显示，在实体瘤全分析集中，体能状态评分为0是一个有利的预后因素（HR=0.209，95%CI=0.065-0.676，p=0.0089），并且可能是辅助治疗中免疫细胞治疗的指征。
展开英文摘要原文
PATIENTS AND METHODS
A total of 141 patients with solid tumors were enrolled in this study. The correlation of overall survival and disease-free survival with various clinical factors such as age, sex, performance status score, clinical stage, treatment strategies, and vital status was investigated by univariate and multivariate analyses.
RESULTS
Multivariate analysis revealed that a performance status score of 0 was a favorable prognostic factor in the full analysis set of solid tumors (HR=0.209, 95%CI=0.065-0.676, p=0.0089) and might be the indication for immune-cell therapy in the adjuvant setting.
CONCLUSION
Adjuvant immune-cell therapy combined with other systemic therapies would potentially provide a survival benefit in patients with solid tumors.
论文信息
- 作者
- Takimoto R、Kamigaki T、Okada S、Ibe H、Oguma E、Goto S
- 单位
- Seta Clinic Group, Tokyo, Japan; takimoto@j-immunother.com.Japan
- 期刊
- Anticancer research2022 Aug
- 原文标识
- PubMed 35896218 · DOI 10.21873/anticanres.15918